Background. Alzheimer's disease (AD) is a progressive neurodegenerative disorder
affecting many individuals worldwide with no effective treatment to date. AD is characterized …

Most neurodegenerative diseases are characterized by intracellular aggregates of insoluble
proteins. As for the majority of these disorders, aetiology and pathogenesis are only poorly …

Alzheimer's disease (AD) is characterized by two molecular pathologies: cerebral β-
amyloidosis in the form of β-amyloid (Aβ) plaques and tauopathy in the form of neurofibrillary …

In 1975, tau protein was isolated as a microtubule-associated factor from the porcine brain.
In the previous year, a paired helical filament (PHF) protein had been identified in …

A panel of radiochemicals has enabled in vivo positron emission tomography (PET) of tau
pathologies in Alzheimer's disease (AD), although sensitive detection of frontotemporal …

The progression of many neurodegenerative diseases is thought to be driven by the
template-directed misfolding, seeded aggregation and cell–cell transmission of …

The advent of tau-targeted positron emission tomography tracers such as flortaucipir (18F-
AV-1451, also known as 18F-T807) have made it possible to investigate the sequence of …

Use of selective in-vivo tau imaging will enable improved understanding of tau aggregation
in the brain, facilitating research into causes, diagnosis, and treatment of major tauopathies …

Hippocampal atrophy, as evidenced using magnetic resonance imaging (MRI), is one of the
most validated, easily accessible and widely used biomarkers of Alzheimer's disease (AD) …

Imaging of neurofibrillary pathology in the brain helps in diagnosing dementia, tracking
disease progression, and evaluating the therapeutic efficacy of antidementia drugs. The …